Acura Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACUR research report →
About the company
Acura Pharmaceuticals, Inc. operates as a drug delivery innovator, dedicated to exploring, developing, and bringing to market novel technologies and products aimed at enhancing medication safety across the United States. Its product portfolio features Oxaydo tablets, a potent Schedule II narcotic prescribed for managing both acute and chronic moderate-to-severe pain.
- CEO
- Robert Jones
- IPO
- 1986
- Employees
- 9
- HQ
- Palatine, IL, US
Price Chart
- Market Cap
- $59.40K
- P/E
- -0.04
- P/S
- 0.04
- P/B
- 0.22
- EV/EBITDA
- -0.33
- Div Yield
- 0.00%
- Gross Margin
- 94.24%
- Op Margin
- -77.67%
- Net Margin
- -56.24%
- ROE
- 30.77%
- ROIC
- -295.38%
- Revenue
- $1.56M · -56.22%
- Net Income
- $-879,000 · 27.24%
- EPS
- $-0.02 · 50.00%
- Op Income
- $-1,214,000
- FCF YoY
- -3.20%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -54.49
- Avg Volume
- 1.17K
Get TickerSpark's AI analysis on ACUR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 2, 26 | THANGARAJ IMMANUEL | other | 50,000 |
| Jan 2, 26 | THANGARAJ IMMANUEL | other | 50,000 |
| Jan 2, 26 | THANGARAJ IMMANUEL | other | 50,000 |
| Jan 2, 26 | SKELLY WILLIAM G | other | 50,000 |
| Jan 2, 26 | SKELLY WILLIAM G | other | 50,000 |
| Jan 2, 26 | SKELLY WILLIAM G | other | 50,000 |
| Jan 2, 26 | ROSS GEORGE K | other | 50,000 |
| Jan 2, 26 | ROSS GEORGE K | other | 50,000 |
| Jan 2, 26 | ROSS GEORGE K | other | 50,000 |
| Jan 2, 25 | THANGARAJ IMMANUEL | other | 50,000 |
Our ACUR coverage
Recent articles, reports, and earnings notes.
No research on ACUR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACUR report →Similar companies
Peers in the same neighborhood.